If the the secondary indications for CKD and cognitive function have good or great numbers; would the follow-up trials for these indications be allowed to start as Phase II or Phase III trials?

I ask this because most Phase I or Phase II trials that I have seen results from seem to be less than six months or one year with limited enrolment numbers. With both of our secondary indications mentioned above there are 400 to 600 patients and potentially more than 3 years of dosing.

Looking forward to the input from those in the science community.